Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 51 to 60 of 75

TitleReference numberPublishedLast updated
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411

Results per page

  1. 10
  2. 25
  3. 50
  4. All